$63 billion! "Drug King" manufacturer stakes revenue from a pharmaceutical company

　　On May 8, AbbVie, the world-renowned maker of "pharma kings", announced that it had completed its acquisition of El Jian Under the terms of the agreement, Aljian shareholders' shares of $193.23 per share will be converted into 0.8660 AbbVie shares and $120.30 in cash (based on the closing price of AbbVie's common stock on May 7, 2020 at $84.22) After the May 8 close, Aljian common stock stopped trading on the New York Stock Exchange
It is understood that the two companies signed a deal on June 25, 2019, under which AbbVie will acquire Aljian Based on the closing price of $78.45 per common stock on June 24, 2019, the value of the stake in the transaction is approximately $63 billion
AbbVie ranks fifth among biopharmaceutical companies with a market capitalisation of $139.6 billion, with total revenue of $32.8 billion in 2018, according to global data analytics firm GlobalData's 2019 list of 25 mandatory pharmaceutical companies ElJian is ranked 19th with a market capitalisation of $45.1 billion, with revenueof $15.8 billion in 2018
The acquisition strengthens and enriches AbbVie's revenue base and complements its dominance in a number of therapeutic areas Among them, in the field of neuroscience, Aer Jian's preservation will bring new growth opportunities, and in the field of aesthetics, Aer Jian brings the global business of such as the advantages of the brand
In addition, the industry believes that, more importantly, AbbVie's reliance on Sumerle is relatively high, the merger will break the bottleneck with a more diversified listed and research portfolio, and can continue to maintain the focus on high-innovation science
Summel (generic name: Adamu mono-resistance) is the world's first approved all-human source anti-tumor necrosis factor alpha (TNFi-alpha) mono-anti-long antibody Because it has been on the world's best-selling list for many years since 2012, it is well known in the industry as the "drug king"
Data show that in 2018, sales of Sumey reached $20.5 billion, nearly $11 billion more than apixaban, and cumulative sales have exceeded $100 billion since its listing It is understood that in the global market, Shu Meile has been approved for treatment of the indications have reached 17, it was included in China's national health insurance directory in 2019, in China approved forrindications include rheumatoid arthritis, strong scoliosis, psoriasis, multi-joint type of juvenile idiopathic arthritis
Although the current sumerle still maintains a good market share in the world, but in 2016, the expiration of the u.S market patent, the world's countries are accelerating the generic research and development of the drug, including the U.S pharmaceutical company Amgen, the German drugfactory Bollinger Ingeheim developed a generic product has been approved It also reflects AbbVie's concern about the heavy reliance on Theummel
The acquisition of El Jian is a start-up in ophthalmology, and later developed into a leading company in the field of medical beauty, the current products are mainly focused on medical beauty, eye care, central nervous system and gastroenterology Injection of type A botulinum toxin to protect fit is one of Aer Jian's well-known products, the current market share is maintained at more than 65% globally, and the global market share of bouric acid injection filler Choyaden is also quite good
Mr AbbVie said a diversified portfolio would drive the company's existing growth platform, with the exception of Sumer, to generate about $30bn in revenue for the full year 2020, with the company likely to exceed $50bn in total revenue With increased operating cash flow, the company expects to be able to pay off incremental debt quickly.